Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Invested Capital (2022 - 2025)

Historic Invested Capital for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $9.0 million.

  • bioAffinity Technologies' Invested Capital rose 12281.27% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 12281.27%. This contributed to the annual value of $3.4 million for FY2024, which is 4316.91% down from last year.
  • bioAffinity Technologies' Invested Capital amounted to $9.0 million in Q3 2025, which was up 12281.27% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Invested Capital ranged from a high of $22.0 million in Q3 2022 and a low of -$2.0 million during Q2 2025
  • Its 4-year average for Invested Capital is $7.2 million, with a median of $6.4 million in 2024.
  • Over the last 5 years, bioAffinity Technologies' Invested Capital had its largest YoY gain of 12281.27% in 2025, and its largest YoY loss of 14382.38% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Invested Capital (Quarter) stood at $11.3 million in 2022, then crashed by 46.38% to $6.1 million in 2023, then tumbled by 43.17% to $3.4 million in 2024, then soared by 162.3% to $9.0 million in 2025.
  • Its Invested Capital stands at $9.0 million for Q3 2025, versus -$2.0 million for Q2 2025 and $2.2 million for Q1 2025.